A quick review of the publicly-traded stem cell stocks I’ve been following in 2021 finds mostly discouraging news, but a few firms relatively outperformed the other publically-traded biotechs. One had some great news today. In this post, I’m doing a brief overview of how things went this year in the regenerative medicine space. I’m going […]
2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best Read More »
One of the most common questions I’ve gotten over the last decade is, “how much does stem cell therapy cost?” They actually seem most often to want to know more specifically how much it should cost. To try to authoritatively answer this now in 2023 we need data from the present and past along with expert
How much does stem cell therapy cost in 2023? Read More »
Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial. Stem cell biotechs These biotechs have ups and downs, sometimes at the same time. This is kind of the standard of “life” as any biotech company. It is definitely the case in the volatile stem cell and cell
24 cell therapy & stem cell stocks I’m following Read More »
At times there’s been seriously bad journalism covering COVID-19 itself including implications of various things being a COVID cure. Of course, media coverage of stem cell research itself sometimes ends up being a train-wreck of hype too. More recently we’ve seen irresponsible journalism also around the specific idea of stem cells for COVID-19, but sometimes
Fact-check: F grade for irresponsible stem cell COVID-19 cure piece Read More »
A new paper today in Stem Cells Translational Medicine on a small COVID-19 Phase 1/2a trial using an umbilical cord stem cell product reports a surprising degree of possible efficacy. What’s the scoop here and could there be some hype in the media about this new study such as one of the authors describing the
Small umbilical cord stem cell COVID-19 trial: sign of efficacy? Read More »
What a year 2020 was, but there was still plenty of great science, which continues now in 2021 including published research like today’s recommended pieces and there’s one thread on MSCs today. The Niche new look, more features, and a Medical Advisory Board for 2021 Before we get to the recommended reads, note that 2021
Recommended reads: MSCs, vision, endothelial cells, more Read More »
Reading to them was one of my favorite things to do with my kids when they were little, but it’s a long way from Goodnight Moon to this week’s list of recommended reads, although “bee brain” may have got their attention. Please take a minute to complete our The Niche reader survey for a chance
Recommended reads: Bee brain, COVID, from Russia with stem cells, pubs Read More »
Another week and more great papers and interesting news in the regenerative medicine sphere including COVID-19 updates, stem cells for vision, and more. Rebuilding Corneas With Stem Cells Stem cell-based regenerative medicine arguably has shown the most promise for vision loss. A PR from Massachusetts Eye and Ear says: Doctors rebuild damaged corneas using patients’
Recommended regenerative medicine reads: COVID-19 updates, Cornea Fix, Pubs Read More »
The FTC has sharply increased its oversight activities against stem cell and regenerative clinic firms. These new actions include quite a few warning letters. Here is the FTC database for COVID-19-related warning letters. Note that recently the FTC added a new, helpful option to view all of its warning letters here. It’s a good source
FTC fires off many warnings to stem cell clinics on COVID-19 Read More »
Today’s post is the latest edition of my weekly recommended reads, which this week include Fate Therapeutics, COVID-19 updates, AAMC, and more including some great pubs such as one on 2 modes of PRC2 function. Also check out this handy resource: Helpful 2020 List of Stem Cell Journals and this blast from the past post of 10
Recommended reads: COVID-19 updates, FDA stem cell nod, PRC2, more Read More »